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Abstract
Protein kinase D (PKD) has been implicated in many aspects of tumorigenesis and progres-
sion, and is an emerging molecular target for the development of anticancer therapy. De-
spite recent advancement in the development of potent and selective PKD small molecule
inhibitors, the availability of in vivo active PKD inhibitors remains sparse. In this study, we
describe the discovery of a novel PKD small molecule inhibitor, SD-208, from a targeted ki-
nase inhibitor library screen, and the synthesis of a series of analogs to probe the structure-
activity relationship (SAR) vs. PKD1. SD-208 displayed a narrow SAR profile, was an ATP-
competitive pan-PKD inhibitor with low nanomolar potency and was cell active. Targeted in-
hibition of PKD by SD-208 resulted in potent inhibition of cell proliferation, an effect that
could be reversed by overexpressed PKD1 or PKD3. SD-208 also blocked prostate cancer
cell survival and invasion, and arrested cells in the G2/M phase of the cell cycle. Mechanisti-
cally, SD-208-induced G2/M arrest was accompanied by an increase in levels of p21 in
DU145 and PC3 cells as well as elevated phosphorylation of Cdc2 and Cdc25C in DU145
cells. Most importantly, SD-208 given orally for 24 days significantly abrogated the growth
of PC3 subcutaneous tumor xenografts in nude mice, which was accompanied by reduced
proliferation and increased apoptosis and decreased expression of PKD biomarkers includ-
ing survivin and Bcl-xL. Our study has identified SD-208 as a novel efficacious PKD small
molecule inhibitor, demonstrating the therapeutic potential of targeted inhibition of PKD for
prostate cancer treatment.
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Introduction
Prostate cancer is the most common male malignancy in western countries [1] and the second
leading cause of cancer death in the US, representing 29% of all male cancer deaths [2]. While
localized disease can be treated by a few modalities, the metastatic stage is palliative rather than
therapeutic and there are currently no effective therapies. Protein kinase D (PKD) is a family of
ubiquitous serine-threonine protein kinase that belongs to the Ca2+/ Calmodulin—dependent
protein kinase superfamily [3]. The three isoforms of PKD (PKD1/PKCµ[4], PKD2 [5] and
PKD3/PKCν [6]) are widely distributed in a variety of tissues, and are homologous in structure
and function. PKDs are activated by protein kinase Cs (PKCs) through phosphorylation of two
conserved serine residues in the activation loop of the kinase domain. For PKD1, activation in-
volves PKC-mediated phosphorylation at Ser738 and Ser742 in the activation loop, followed by
autophosphorylation at Ser910 that conveys full activation [7,8].
PKD plays an important role in mediating mitogenic signaling and has been shown to potentiate
the GPCR-induced cell proliferation through theMEK/ERK/RSK pathway [9]. Emerging evidence
demonstrates the involvement of PKD in key signaling pathways that regulate tumor cell prolifera-
tion such as β-catenin, androgen receptor, mTORC1-S6K1, andMAPK in various tumor cell models
[10–15]. Collectively, this mechanistic footprint demonstrates an important role of PKD in cancer,
providing the foundation of targeting PKD using small molecule inhibitors for cancer therapy.
In recent years, the development of small molecule inhibitors that target the PKD family has
advanced significantly [15–19]. After the discovery of the first potent, selective, and cell-active
small molecule inhibitor CID 755673 by our group [20,21] we directed significant efforts at im-
proving its potency and selectivity through chemical modifications. While we developed leads
with much improved potency and selectivity, such as kb-NB142-70 [20,22], the in vivo efficacy
and applicability of this class of inhibitors remained limited [23]. A recent study utilizing tar-
geted libraries of small organic kinase inhibitors has also identified a novel ATP-competitive 4-
azaindole scaffold, and a set of pyrazolopyrimidine small molecule inhibitors with low nano-
molar potency for in vitro inhibition of PKD that potently blocked prostate cancer cells prolif-
eration and growth [18,24,25]. Despite the immense efforts toward the development of potent
and selective PKD small molecule inhibitors for cancer therapy, there remains great demand
for efficacious in vivo-active PKD small molecule inhibitors able to progress into preclinical de-
velopment and further into the clinical application.
In the present study, we identified SD-208 as a novel ATP-competitive PKD small molecule
inhibitor in vitro and in vivo. In prostate cancer cells, we showed that SD-208 significantly
suppressed tumor cell proliferation through targeted inhibition of PKD and blocked tumor
cell invasion. A mechanistic investigation suggested that SD-208 abrogated cancer cell prolifera-
tion through inducing G2/M cell cycle arrest by increasing cyclin-dependent kinase inhibitor
(CDKI)—p21 levels and modulating the activity of Cdc25C/Cdc2 pathway. Further, SD-208
blocked PC3 prostate cancer cell proliferation and the growth of tumor xenografts in nude mice,
correlating to decreased Bcl-xL and survivin. We also generated a series of analogs of SD-208 by
chemical synthesis, and evaluated their inhibitory profile, demonstrating a narrow SAR for this
lead structure. Our results thus characterize SD-208 as a structurally new PKD small molecule in-
hibitor that significantly abrogates prostate cancer cell proliferation in vitro and in vivo.
Materials and Methods
Ethics Statement
This study was carried out according to Institutional Animal Care and Use Committee
(IACUC) at the University of Pittsburgh guidelines and the animal protocol and study was
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Editorial policies and criteria.
approved by University of Pittsburgh Institutional Animal Care and User Committee (Protocol
Number: 11120102).
Cell culture and reagents
Human prostate carcinoma PC3, DU145 and LNCaP cells were obtained from American Type
Culture Collection (ATCC) and cultured according to the manufacturer’s recommendation.
All cell lines were grown at 37°C, 5% CO2 in a humidified atmosphere. Ham’s F-12 and MEM
were from Cellgro (Manassas, VA) and other culture materials were from Invitrogen (Life
Technologies, Carlsbad, CA). Kinase active recombinant GST-tagged human protein kinase
D1 (PKD1) was obtained from Enzo Life Sciences (Farmingdale, NY). DMSO was purchased
from Sigma (Sigma-Aldrich, St. Louis, MO). Recombinant PKCα, PKCδ, and CAMKIIα were
obtained from SignalChem (Richmond, BC, Canada). ATP was purchased from Fisher Scien-
tific (Fair Lawn, NJ). HDAC5 substrate peptide was synthesized by Biobasic Canada Inc.
(Markham, ON). Myelin basic protein 4–14 was purchased from AnaSpec Inc. (Fremont, CA).
A pharmacologically active kinase inhibitor library was purchased from Tocris Bioscience
(Minneapolis, MN).
Synthesis of SD-208 Analogs
We decided to chemically modify the 5-chloro-2-fluorophenyl (zone 1) and the para-amino-
pyridine (zone 2) moieties of SD-208 to probe the contributions of these side chains to PKD1
inhibition (Table 1 and S1 Fig.). Details of synthesis are described in the Supporting
Information.
Docking of SD-208
This study was conducted as previously reported [25]. The structural homology model of
PKD1’s kinase domain (residues 587 to 835) was generated using the I-TASSER server. Sybyl-
X 2.1 Surflex-Dock software performed the docking of SD-208 into PKD1’s kinase domain.
Program settings were configured under the subsequent parameters. All hydrogen atoms were
Table 1. Overview of structures and yields of intermediates 3 and 4 (shown in “S1 Fig.”) and analogs 5 (as described in “Supporting
Information”) with PKD1 inhibition data for analogs 5.
Entry Compound R1 R2 Yields 3 (%) Yields 4 (%) Yields 5 (%) % PKD1 Inhibition
1 SD-208 (2-F-5-Cl)Ph 4-Pyridyl 78 86 40b 74%
2 5a Ph Ph 72 74 40c  10
3 5b Ph c-Hexyl 72 74 21c  10
4 5c Ph 4-Pyridyl 72 74 71b  10
5 5d Ph 3-Pyridyl 72 74 65b  10
6 5e (2,5-F2)Ph 4-Pyridyl 57 50 <5
b 60
7 5f (2,5-F2)Ph 3-Pyridyl 57 50 51
b  10
8 5g (2,5-F2)Ph 2- Morpholinoethyl 57 50 52
b  10
9 5h (3-CF3)Ph 4-Pyridyl 56 53 23
b 60
10 5i (3,5-Cl2)Ph 4-Pyridyl 61 54 <5
b  10
11 5j (2-F-5-Cl)Ph Piperazinyla 78 86 13b  10
aPiperazine is directly connected to the pteridine core without a secondary amine.
bVia the PyBOP route.
cVia the chlorination/substitution route (2-step yield).
doi:10.1371/journal.pone.0119346.t001
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present in both the homology model as well as SD-208. The docking area was restricted within
the confines of the ATP binding site, which include the following residues: Ala610, Lys612,
Met659, Glu660, Lys661, Leu662, His663, Glu710, Leu713, and Cys726. Twenty additional starting
conformations were evaluated for SD-208 and all binding modes were assessed. Molecular
modeling was presented using PyMol.
In Vitro Radiometric PKD Inhibitor Screening Assay
An in vitro radiometric PKD kinase assay was used to screen a small library of 80 commercially
available kinase inhibitors, Tocriscreen kinase inhibitor collection (Tocris Biosciences, Minne-
apolis, MN), for PKD1 inhibitory activity at 1 µM concentration [24]. In Vitro Radiometric
protocol is described in the Supporting Information.
Western Blot Analysis
LNCaP and DU145 prostate cancer cells were maintained in RPMI 1640, while PC3 cells were
maintained in Ham’s F-12 medium, supplemented with 10% fetal bovine serum (FBS) and
1000 units/L penicillin, and 1 mg/mL streptomycin in 5% CO2 at 37°C. AWestern blot analysis
was carried out as previously reported [10]. Primary antibodies targeted p-S916-PKD1 (human
p-S910-PKD1) (Millipore), p-S744/748-PKD1 (human p-S738/742-PKD1), PKD1, pHsp 27, Hsp
27,p21, Cyclin A2, p-Cdc2, Cdc2, Cyclin B1, p-Cdc25C, Cdc25C, Survivin, Bcl-XL, Akt and p-
S473-Akt (Cell Signaling Technology), PKD2 (Abcam), Cyclin D1 (Santa Cruz Biotechnology,
Dallas, TX), GAPDH (Enzo Life Science, Farmingdale, NY) and tubulin (Sigma) were used
for blotting.
In Vitro Radiometric PKC and CAMKIIα Kinase Assay
The PKC kinase assay was carried out by co-incubating 1 µCi [γ-32P]ATP, 20 µM ATP, 50 ng
of purified PKCα or PKCδ and 5 µg of myelin basic protein 4–14, 0.25 mg/mL bovine serum al-
bumin, 0.1 mg/mL phosphatidylcholine/phosphatidylserine (80/20%) (1 µM), 1 µM phorbol
dibutyrate in 50 µL of kinase buffer containing 50 mM Tris-HCl, pH 7.5, 4 mMMgCl2 and
10 mM β-mercaptoethanol. For the CAMK assay, 50 ng of CAMKIIα and 2 µg syntide-2 sub-
strate in 50 µL kinase buffer were incubated with 0.1 mMMgCl2, 1 µCi of [γ-
32P] ATP, 70 µM
ATP. 0.5 mM CaCl2 and 30 ng/µL calmodulin were preincubated for 15 min on ice and then
added in the kinase reaction. The reactions were incubated at 30°C for 10 min and 25 µL of the
reaction was spotted on Whatman P81 filter paper. The filter paper was washed 3 times in
0.5% phosphoric acid, air dried and counted using Beckman LS6500 multipurpose scintillation
counter.
MTT Assay
PC3 cells were seeded into 96-well plates (3000 cells/well) and allowed to attach overnight.
Cells were then incubated in media containing 0.7–100 μM inhibitors for 72 h. 50 μL of 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide methyl thiazolyl tetrazolium (MTT)
solution at 2 mg/mL concentration was added to each well and incubated for 4 h at 37°C.
Then, media was removed and 200 μL DMSO was added to each well. The plate was mixed by
shaking for 5 min and the optical density was determined at 570 nm.
Subcutaneous Prostate Tumor Xenograft Study
Athymic NCr-nu/nu mice (4–6 week old) (NCI, Frederick, MD) were injected subcutaneously
with 1.4 X 106 PC3 cells in 100 µL media. Three days after inoculation, when tumors became
SD-208 as a Novel PKD Inhibitor in Prostate Cancer
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palpable, the mice were randomized into the following groups (5 mice per group); (a) vehicle
(control) 1% (w/v) methylcellulose administered by oral gavage twice daily; (b) SD-208
60 mg/kg suspended in 1% methylcellulose administered by oral gavage twice daily, for 21
days. Body weights were measured twice weekly. Tumors were measured in two dimensions
every 2 to 3 days by calipers and tumor volume was calculated as V (mm3) = (L XW2)/2. The
tumor volumes were compared at each time point among groups using unpaired t test and a
p value of< 0.05 was considered statistically significant. Twenty-four days after inoculation,
mice were euthanized by CO2 inhalation and tumors were excised. All animal studies were con-
ducted in accordance with an Institutional Animal Care and Use Committee (IACUC) at the
University of Pittsburgh.
Immunohistochemical (IHC) Staining of Tumor Tissues
Formalin-fixed and paraffin embedded sections were stained as described earlier [10]. Briefly,
sections were deparraffinized by xylene and rehydrated in reducing gradients of ethanol. Anti-
gen retrieval was performed by simmering the slides at near boiling temperature for 30 min in
10 nmol/L sodium citrate buffer (pH 6.0), followed by cooling to room temperature. Tissue sec-
tions were then stained with Ki-67 (Genetex, Irvine, CA) and cleaved caspase-3 (Cell signaling
Technology, Beverly, MA) antibodies at 4°C overnight and then incubated with biotinylated
goat anti-rabbit antibody (Vector laboratories, Logan, UT). The slides were then developed
using Vectastain ABC Standard kit and AEC Reagent (Scytek Labs,Logan, UT). The tissues
were finally counterstained with hematoxylin. A total of 10 fields were examined and counted
from each treatment groups in a blinded fashion.
Immunoprecipitation and p-PKD2 Kinase Assay
PKD2 was immunoprecipitated by incubating 500 μg of total cell lysates from tumor explants
with protein A/G Sepharose beads (Santa Cruz Biotechnology, Inc.) preconjugated with anti-
PKD2 antibody (GeneTex, Irvine, CA.) overnight at 4°C with constant rotation. The immuno-
complexes were then pelleted and washed with washing buffer (50 mM Tris-HCl, pH 7.4, 150
mM sodium chloride, and 1% Triton X-100). Equal amounts of immunocomplex were then
subjected to PKD kinase assay, as described in supplement protocol. In brief, the assay was car-
ried out by coincubating 20 μl of immunoprecipitated PKD2 with 25 μMATP, 0.2 μl of [γ-32P]
ATP (PerkinElmer Life and Analytical Sciences, Boston, MA) and 1.2 μM a 25 a.a. HDAC-5
peptide as substrate [26] in a final volume of 50 μl. The reaction was allowed to proceed at
30°C for 10 min. An aliquot of the reaction mixture was then spotted on p81 paper, washed in
5% phosphoric acid and counted.
Cell Proliferation Assay and Cell Cycle Analysis
Proliferation of PC3 cells was measured by counting the number of viable cells upon trypan
blue staining as previously described [10]. Cell cycle analysis was performed as described [22].
Briefly, PC3 cells were treated with the appropriate compounds at 30 μM for 72 h, and then
fixed in 70% ice-cold ethanol overnight, followed by labeling with propidium iodide. The la-
beled cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA).
Matrigel Invasion Assays
Matrigel invasion assay was conducted as previously described [21,22] (see Supporting Infor-
mation for more details).
SD-208 as a Novel PKD Inhibitor in Prostate Cancer
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Statistical analysis
Statistical analysis was completed using GraphPad Prism software 5.0. A p value of< 0.05 was
considered statistically significant.
Results
Identification of SD-208 as a novel PKD small molecule inhibitor
We conducted a screen of PKD small molecule inhibitors on Tocriscreen kinase inhibitor col-
lection of 80 chemically diverse kinase inhibitors at 1 µM concentration using an in vitro radio-
metric PKD kinase assay. With a cut-off set at 50% inhibition of total PKD1 kinase activity,
16 compounds were identified as primary hits. Among them, SD-208 suppressed 82% of PKD1
activity at 1 μM concentration (data not shown) and was further evaluated for inhibition of
PKD1, 2 and 3 in a 10-point concentration curve using the radiometric PKD kinase assay [21].
As shown in Fig. 1A, SD-208 inhibited PKD1, 2, and 3 with an IC50 of 106.87 ± 6.6 nM (n = 9),
93.54 ± 2.7 nM (n = 9), and 105.3 ± 2.6 nM (n = 9), respectively. Using LNCaP prostate cancer
cells as the model system, the effect of SD-208 on 12-myristate 13-acetate (PMA)-induced en-
dogenous PKD1 activation was examined as previously described [10,22]. As shown in
Fig. 1B-C, treatment of LNCaP cells with 10 nM of PMA for 20 min induced robust PKD1 ac-
tivation, detected by increased PKD1 activation loop phosphorylation at Ser738/742 conferred
by PKC and C-terminal autophosphorylation at Ser910. Pretreatment with increasing concen-
trations of SD-208 concentration-dependently inhibited autophosphorylation at Ser910 of
PKD1 with an IC50 of 17.0 ± 1.5 μM (Fig. 1C). In contrast, PKC-dependent trans-phosphoryla-
tion at Ser738/742 was unaffected by SD-208, indicating that SD-208 directly abrogated PKD1
catalytic activity without blocking upstream PKC-mediated PKD1 trans-phosphorylation.
Thus, SD-208 is structurally distinct pan-PKD inhibitor that elicits targeted inhibition of
PKD1 kinase activity in prostate cancer cells.
SD-208 was an ATP-competitive inhibitor with high selectivity for PKD
over closely related kinases
To gain a better insight on the mode of action for SD-208, we examined the effects of increas-
ing concentrations of ATP on PKD1 inhibition. Lineweaver-Burk plots were generated by plot-
ting the reciprocal of reaction velocities (1/v) against the reciprocal of ATP concentrations (1/
[ATP]) at different compound concentrations. The points were fitted by linear regression. As
shown Fig. 1D, all lines converged on the Y-axis, indicating that SD-208 was an ATP-competi-
tive inhibitor. Next, we determined the specificity of SD-208 for PKD by examining their activ-
ity for the classical and novel PKC isoforms using PKCα and PKCδ. No significant inhibitory
activities for PKC isoforms were detected at 0.1 and 1 μM and for PKCα at 10 μM (Fig. 1E-F).
The potent PKC inhibitor GF109203X was tested as a positive control and it potently and con-
centration-dependently inhibited PKCα and PKCδ. High sequence homology of PKD with the
CAMK family led us to investigate the inhibition of CAMKIIα by SD-208. As illustrated in
Fig. 1G, SD-208 showed no activity on CAMKIIα up to 10 μM. Taken together, these data in-
dicate that SD-208 is a highly specific inhibitor for PKD relative to other closely related kinases
including PKCs and CAMKs.
Synthesis, SAR analysis, and modeling of SD-208 and its analogs
Our approach to the synthetic studies, as detailed in S1 Fig., was based on two zones of substi-
tution in SD-208, where the 2-fluoro-5-chlorobenzene represents zone 1 and 4-aminopyridine
represents zone 2 (Fig. 2). Using the pteridine core as a synthetic platform, we were interested
SD-208 as a Novel PKD Inhibitor in Prostate Cancer
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in exploring the substitutions attached to the fused pyrimidine ring, specifically to identify the
SAR contributions of the fluorine and chlorine substituents in zone 1 and the pyridine ring in
zone 2. The secondary amine in zone 2 was preserved because amino substitutions alpha to ni-
trogen atoms in heterocycles are often implicated in protein kinase hinge binding [27,28]. As a
consequence, the secondary amine may prove essential for activity.
Our SAR investigation initially focused on the importance of the substituents on the aro-
matic ring in zone 1 (Table 1). The electron density of the aromatic ring in SD-208 is decreased
by the electronegativity of the fluorine atom [29,30]. Moreover, chlorine may contribute to di-
pole-dipole interactions in the protein binding cleft [31]. Removal of the halogens from the
benzene ring (5a-d) led to a significantly decreased activity. In contrast, installation of electron
withdrawing groups such as fluorine (5e-g) and trifluoromethyl (5h) restored activity, but only
when zone 2 was comprised of 4-aminopyridine (5e,h). Interestingly, only 4-aminopyridine
was tolerated in zone 2. Therefore, our attempts to improve the solubility with piperazine (5j)
and 2-morpholinoethyl (5g) substituents failed to conserve PKD1 inhibitory effects. Surpris-
ingly, even a regioisomer, 3-aminopyridine (5d,f), was not tolerated. This observation suggests
that the nitrogen in the pyridine ring may be involved in essential hydrogen bonding interac-
tions, but only in a specific spatial arrangement. Additional diversification of zone 1 with
3,5-dichloro substituents (5i) did not restore activity. This further supports the importance of
the electron-withdrawing group since chlorine is less electronegative than fluorine. Changing
Fig 1. SD-208 was a cell-active, ATP-competitive PKD inhibitor and did not inhibit PKC and CAMK. A. Determination of PKD kinase activity in vitro.
Inhibition of recombinant human PKD1, 2 and 3 was assayed in the presence of 10 different concentrations of SD-208 by an in vitro radiometric PKD kinase
assay. The IC50 values were calculated as the mean ± SEM of at least three independent experiments with triplicate determinations at each compound
concentration in each experiment. The data were plotted as a function of inhibitor concentration and a representative graph is shown.B. SD-208 inhibited
PMA-induced PKD1 activation in prostate cancer cells. LNCaP cells were pretreated with different doses of inhibitors for 45 min, followed by PMA
stimulation at 10 nM for 20 min. Cell lysates were subjected to immunoblotting for p-S910-PKD1 and p-S738/742-PKD1. Tubulin was blotted as loading control.
The experiment was repeated three times and the representative blots are shown.C. Determination of cellular IC50. Western blots from ‘B” were quantified
using densitometry analysis. The data were plotted and IC50 values were derived from the concentration-response curves using GraphPad. One of the three
concentration-response curves is shown.D. SD-208 is an ATP-competitive kinase inhibitor. PKD1 kinase activity was measured as a function of
increasing concentrations of ATP in the presence of varying concentrations of SD-208. Lineweaver-Burke plots of the data are shown. Data presented were
the mean ± S.E. of three independent experiments with triplicate determinations at each data point in each experiment. E-F. Selectivity of SD-208 against
related kinases. Inhibition of PKCα (B) or PKCδ (C) was determined at 10 nM, 100 nM, 1μM, and 10 μM. As controls, the PKC inhibitor GF109203X potently
inhibited PKCα and PKCδ activity. Data are the mean ± SEM of two independent experiments.G. Inhibition of CAMKIIαwas measured by the radiometric
CAMK kinase assay. Data are the mean ± S.E. of two independent experiments with triplicate determinations at each data point in each experiment.
Statistical significance was determined using the unpaired t-test. ns, not significantly significant; *, p<0.05; **, p<0.01; ***, p<0.001.
doi:10.1371/journal.pone.0119346.g001
Fig 2. Scope of first-generation SAR studies on SD-208. 2-Zone model for SD-208 analog synthesis.
doi:10.1371/journal.pone.0119346.g002
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the positions of substituents on the benzene ring in the 2,5-difluoro- (5e) and 3-trifluoro-
methyl- (5h) analogs conserved activity. This result indicates that the position of the substitu-
ents on this arene may not be critical as long as the functional group is sufficiently electron-
withdrawing.
In conjunction with this SAR analysis, we employed our PKD1 homology model [25] to ra-
tionally explore a putative binding mode of SD-208 within the active site of PKD1. Common
among ATP-competitive inhibitors, SD-208 was shown in Fig. 3A to interact with the hinge re-
gion through hydrogen bond formation between the amino acid backbone of Leu662 and its
pteridine core. Additionally, a potentially critical hydrogen bond was observed with the nitro-
gen from the 4-aminopyridine and the charged side chain of Lys612. A similar interaction was
also reported in other known PKD1 inhibitors [18]. Our SAR analysis further supports the no-
tion that the nitrogen from the 4-aminopyridine acts as a valuable hydrogen bond acceptor.
Ablation of this bond revealed a marked decrease in PKD1 inhibition. Moreover, displayed in
Fig. 3B, our model positions the disubstituted phenyl ring in a hydrophobic pocket consisting
of Leu589 and Leu713, which may dictate the tolerance of aromatic substitutions. Although
other binding modes of SD-208 were explored, the current model best recapitulated results rep-
resented in our SAR analysis.
SD-208 inhibited prostate cancer cell proliferation and invasion
We next investigated the effects of targeted inhibition of PKD by SD-208 on prostate cancer
cell proliferation, survival, and cell cycle progression. As shown in Fig. 4A-B, SD-208 at 30 μM
caused significant reduction in PC3 prostate cancer cells proliferation starting at day 2 and per-
sisted to the end of the experiment. SD-208 also concentration-dependently induced cell death
with an IC50 of 17.0 ± 5.7 μM (n = 3) (Fig. 4C). The effect of SD-208 on tumor cell invasion
was assessed using Matrigel invasion assay (cell invasion). As illustrated in Fig. 4D, treatment
of cells with 30 μM SD-208 for 20 h resulted in over 60% inhibition of cell invasion compared
with control, indicating that SD-208 significantly blocked tumor cell invasion. Taken together,
our data demonstrates that SD-208 is a potent inhibitor of prostate cancer cell proliferation
and invasion.
Fig 3. Molecular modeling of SD-208 in the active site of a PKD1 homologymodel. This depiction demonstrated a potential binding mode of SD208 in
the active site of PKD1. Red dotted lines represent key interactions between SD-208 and PKD1.
doi:10.1371/journal.pone.0119346.g003
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SD-208-induced growth arrest was mediated through targeted inhibition
of PKD
To determine the target specificity of SD-208 at the cellular level, we sought to investigate if
SD-208-induced anti-proliferative effects were mediated though targeted inhibition of PKD.
An attempt was made to reverse the effect of the PKD inhibitor via overexpressing different
PKD isoforms. As shown in Fig. 4E-F, PC3 cells were infected with null adenovirus (Adv-null)
and adenovirus carrying PKD1 and PKD3 genes (Adv-PKD1 and Adv-PKD3) at 50 and 100
MOI. Western blotting revealed overexpression of PKD1 and PKD3 in PC3 cells infected with
adenoviruses carrying the respective genes. The infected cells were subjected to SD-208 treat-
ment at 10 and 30 μM. Expression of increasing levels of PKD1 and PKD3 reversed the anti-
proliferative effects of SD-208. The higher levels of PKD1 or PKD3 expression, the greater the
rescue effects, and at 100 MOI a nearly complete reversal of inhibition of cell proliferation was
observed for Adv-PKD3 at 10 and 30 µM SD-208 (Fig. 4). These data indicate that the anti-
proliferative effects of SD-208 are mediated through the inhibition of PKD. In order to deter-
mine whether anti-proliferative property of SD-208 is due to targeted inhibition of PKD, we
seek to determine if it also inhibited PKDmediated PMA-induced Hsp27 phosphorylation at
Ser-82 in prostate cancer cells (Yuan and Rozengurt, 2008). Hsp27 is a well established direct
substrate of PKD [32,33]. Cultures of DU145 cells were treated in the absence or in the pres-
ence of increasing concentration of SD-208 for 45 min and then stimulated with 100 nM PMA.
As indicated in Fig. 4G treatment of prostate cancer cells with PMA for 20 min induced robust
PKD1 and Hsp27 activation, detected by increased PKD1 autophosphorylation at Ser910 and
Hsp27 phosphorylaion at Ser82. However pretreatment with increasing concentrations of SD-
208 concentration-dependently inhibited PKD induced activation of Hsp27 at Serine 82 along
with PKD1 and PKD2 phosphorylation at Serine 910 and Serine 876, respectively. Similar re-
sults were also observed when LnCAP and PC3 cells lines were treated with SD-20 (S2 and S3
Figs.). Our data, for the first time, demonstrates the specificity the inhibitory effects of SD-208
on PKD and its direct target Hsp27.
Fig 4. SD-208 inhibited prostate cancer cells proliferation, survival, and invasion and the anti-proliferative effect of SD-208 wasmediated through
the inhibition of PKD. A-B. SD-208 inhibited PC3 (A) and LNCaP (B) prostate cancer cell proliferation. PC3 and LNCaP cells were plated in triplicates
in 24-well plates. Cells were allowed to attach overnight. A cell count at day 1 was made, and then either a vehicle (DMSO) or SD-208 at 30 μMwas added.
Cells were counted daily for a total of 6 days. Data are the mean ± S.E. of two independent experiments with triplicate determinations at each data point in
each experiment.C. SD-208 inhibited PC3 prostate cancer cell survival. PC3 cells were seeded into 96-well plates (3000 cells/well) and were then
incubated in media containing 0.3–100 μM inhibitors for 72 h. MTT solution was added to each well and incubated for 4 h. Optical density was read at 570 nm
to determine cell viability. The IC50 was determined as the mean of three independent experiments for each compound. D. SD-208 inhibited prostate
cancer cell invasion. DU145 cells were incubated with 30 μMSD 208 in Matrigel inserts. After 20 h, noninvasive cells were removed and invasive cells were
fixed in 100%methanol, stained in 0.4% hematoxylin solution, and photographed. The number of cells that invaded the Matrigel matrix was determined by
cell counts in 6 fields relative to the number of cells that migrated through the control insert. Percentage invasion was calculated as the percent of the cells
invaded through Matrigel inserts vs. the total cells migrated through the control inserts. Data are the mean ± S.E. of three independent experiments with
triplicate determinations at each data point in each experiment. Statistical significance was determined using the unpaired t-test. ***, p<0.001. E-F.
Overexpression of PKD1 and PKD3 in prostate cancer cells rescued the anti-proliferative effects of SD-208. PC3 (0.5 million) cells were seeded in a
60 mm dish and infected the next day with 50 and 100 MOI of PKD1 and PKD3 adenoviruses (Adv-PKD1 and Adv-PKD3). Empty adenovirus (Adv-null) was
used as control. After 24 h, 3000 cells/well were plated in 96-well plates and treated with and without 10 and 30 μMSD-208 for 72 h. MTT solution was added
to each well and incubated for 4 h. Optical density was read at 570 nm to determine cell viability. The overexpression of PKD1 and PKD3 was confirmed by
Western blotting analysis. This experiment was repeated three times and data are the mean ± S.E. of all three independent experiments. Statistical
significance between DMSO and inhibitor treatment was determined using the unpaired t-test.*, p<0.05; **, p<0.01; ***, p<0.001.G. PKDmediated
Hsp27 activity in prostate cancer cells was inhibited by SD-208. DU145 cells were pretreated with different doses of inhibitors for 45 min, followed by
PMA stimulation at 10 nM for 20 min. Cell lysates were subjected to immunoblotting for p-S910-PKD1 and p-S738/742-PKD1. GAPDHwas blotted as loading
control. The experiment was repeated two times and the representative blots are shown.
doi:10.1371/journal.pone.0119346.g004
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SD-208 caused G2/M cell cycle arrest by inducing Cip1/p21 and
upregulating Cdc25C/Cdc2 pathway activity
To gain insights in SD-208-induced growth inhibition, we determined the effect of SD-208 on
cell cycle progression by flow cytometry. As shown in Fig. 5A-B, cell cycle analysis was con-
ducted after treating DU145 and PC3 cells with 30 μM of SD-208 for 72 h. SD-208 hampered
cell cycle progression by arresting the cells in G2/M phase of the cell cycle. Specifically, SD-208
significantly increased the proportion of cells in G2/M phase of the cell cycle from 18.78% (ve-
hicle treated cells) to 30.09% in DU145 cells and 6.3% (vehicle treated cells) to 35.6% (30 µM
SD-208 treated cells) in PC3 cells, implying that the growth inhibition caused by SD-208 in
prostate cancer cells is a consequence of an arrest of cells in G2/M phase of cell cycle.
Cell cycle G2/M transition is positively regulated by CDK 1 (Cdc2) and Cyclin B complex.
Cdc25 family of phosphatases plays a crucial role in cell cycle regulation through dephosphory-
lation of the inhibitory phosphorylations on Cdc2 at Thr14 and Tyr 15, caused by Wee1 [34].
Moreover, cyclin dependent kinase inhibitor (CDKI), Cip1/p21, also regulates the transitions
of G2/M phase by binding and inhibiting the activity of Cdc2-Cyclin B1 complex [35,36]. To
determine the mechanisms through which SD-208 induced G2/M arrest in prostate cancer
cells, we next assessed the impact of SD-208 on cell cycle machineries at the G2/M transition in
DU145 and PC3 prostate cancer cells, which have similar PKD isoform expression patterns
[10] As shown in Fig. 5C-D, treatment with increasing concentrations of SD-208 for 24 and 48
h induced the expression of Cip1/p21 in a concentration-dependent manner. Additionally, in
both the cell lines, SD-208 treatment for 24 and 48 h caused a concentration-dependent de-
crease in Cdc25C and p-Cdc25C levels, accompanied by a parallel increase in p-Cdc2. These
findings suggest that the induction of Cip1/p21, together with the decreased Cdc25C protein
and consequently increased phosphorylation of Cdc2 and inhibition of Cdc2/cyclin B1, are the
main mechanisms that accounts for the induction of G2/M phase cell cycle arrest by SD-208.
SD-208 inhibited the growth of tumors in a subcutaneous prostate
cancer xenograft model
Athymic NCr-nu/nu mice (4–6 weeks old) were inoculated subcutaneously with 1.4 X 106 PC3
cells. Once tumors are palpable (approximately four days after inoculation), mice were ran-
domized into 2 groups of 5 mice and administered orally with vehicle or 60 mg/kg of SD-208.
As shown in Fig. 6A-C, oral administration of SD-208 for 21 days showed a time-dependent
inhibition of tumor growth. A statistically significant reduction in tumor volume was observed
at day 11 in the treated group. This effect was sustained through the end of the treatment,
while no sign of toxicity was observed throughout the treatment period as depicted by a stable
bodyweight (Fig. 6D). To determine if the growth inhibition was correlated to reduced cell
proliferation and resistance to apoptosis, we sought to examine markers of tumor cell prolifera-
tion (Ki-67) and apoptosis (cleaved caspase-3) in PC3 tumor tissues treated with or without
SD-208 by immunohistochemistry (IHC). As shown in Fig. 6E-F, IHC staining of cleaved cas-
pase-3 showed increased apoptosis in tumor explants of the treated group as compared with
the control. In accordance, a significant reduction in Ki-67 positive cells was observed in SD-
208-treated groups of tumors, indicating inhibition of tumor cell proliferation by SD-208. Pro-
teins such as survivin and Bcl-xL have been found to be associated with tumor survival, che-
moresistance, and radioresistance [37] and have been described as biomarkers for PKD [15].
SD-208 treatment led to a moderate decrease in the protein expression level of these proteins
in the treatment group compared to the control group (Fig. 6G). Also, decreased levels of p-
S473-Akt and Akt were observed in SD-208 treated group as compared to the control, which is
in concurrence of our previous study where PKD3 was shown to modulate Akt activity [10].
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Fig 5. SD-208 arrested cells in G2/M and regulated the levels and activities of cell cycle regulatory proteins at the G2/M phase of cell cycle in
prostate cancer cells. A-B. SD-208 induced G2/M cell cycle arrest in prostate cancer cells. DU145 cells (A) and PC3 cells (B) were treated with either
vehicle (DMSO) or 30 μMSD 208 for 48 h. Cell cycle distribution was determined by flow cytometry after propidium iodide labeling of fixed cells. The cell
cycle plots are representative of three independent experiments (left). Data in the bar graph are the mean ± SEM of three independent experiments (right).
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These effects of SD-208 on Bcl-xL, survivin, Akt, and p-Akt levels may, in part, account for its
pro-apoptotic and antitumor activity in PC3 xenograft tumors. To demonstrate that SD-208
inhibited the intended target—PKD, we also determined the effect of SD-208 on PKD activity
Fig 6. SD-208 inhibited the growth of PC3 tumor xenografts in vivo. A-D. Effects of SD-208 on the growth of PC3 tumor xenograft. PC3 cells (1.4 X
106) were injected s.c. to both flanks of nude mice. Once tumors were palpable, mice were randomized into two groups (5 mice/group) and were administered
0.2 ml twice daily doses of vehicle [1% (w/v) methylcellulose] or SD-208 (60 mg/kg) by oral gavage. Tumor volume (C) and mouse weight (D) were measured
every 2 to 3 days. Twenty-four days after treatment, mice were euthanized by CO2 inhalation, and tumors were excised. Images of representative mice (A)
and dissected tumors (B) are shown. All animal studies were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC).
Statistical significance was determined using the unpaired t-test. **, p<0.01; ***, p<0.001. E, Analysis of apoptotic marker cleaved caspase-3 by IHC.
Quantification of in situ cleaved caspase-3-positive cells as described inMaterials and Methods. Representative images of cleaved caspase-3 staining
(x200) are shown. F, Analysis of proliferative marker Ki67 by IHC. Quantification of Ki-67-positive cells or proliferation index as described inMaterials and
Methods. Representative images of Ki-67 staining (x200) are shown.G. Analysis of PKD-regulated biomarkers in PC3 tumor xenografts. Cell lysates
were prepared from tumor explants obtained from vehicle and SD-208-treated mice. Levels of PKD-regulated proteins were analyzed byWestern blotting
analysis. The densitometry data represents ‘fold change’ as compared with vehicle control after normalization with GAPDH as loading control.H. Effect of
SD-208 on the PKD2 activity in PC3 tumor xenografts. Cell lysates from tumor explants obtained from vehicle and SD-208-treated mice were
immunoprecipitated with PKD2 antibody followed by in vitro kinase assay as described in Material and Methods. The experiment was repeated three times
and data are the mean ± S.E. of all three independent experiments with triplicate determinations at each data point in each experiment.
doi:10.1371/journal.pone.0119346.g006
Statistical significance was determined using the unpaired t-test and is indicated. **, p<0.01; ***, p<0.001.C-D. Effects of SD-208 on the expression and
activities of G2/M cell cycle regulatory proteins. DU145 (C) and PC3 (D) cells were treated with DMSO or 5–30 µMSD-208 for 24 and 48 h. At the end of
each treatment, cells were harvested and subjected to immunoblotting for the cell cycle regulatory proteins as indicated. GAPDHwas blotted as loading
control. The densitometry data (mean ± SEM from four experiments) were plotted as ‘fold change’ over the control after normalization with GAPDH. The
experiments were repeated four times and representative blots from one experiment are shown.
doi:10.1371/journal.pone.0119346.g006
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in tumor xenograft tissues. PKD2 was immunoprecipitated and subjected to in vitro PKD ki-
nase assay. As shown in Fig. 6H, treatment with SD-208 significantly suppressed PKD2 activity
in treated- vs. untreated-tumors, suggesting that SD-208 has reached the intended target and
the inhibition of PKD may account for growth reduction of tumor xenografts.
Discussion
Dysregulation of protein kinase D (PKD) contributes to sustained cell proliferation in multiple
cellular systems including cancer [10,38,39]. Increasing evidence support the potential of PKDs
as therapeutic target to combat various types of cancers including prostate cancer. Although
several PKD small molecular inhibitors have been reported in the past, none have progressed
to the clinic. This is mainly due to the lack of in vivo activity and sufficient therapeutic efficacy
in these inhibitory chemotypes. To date, CRT0066101 remains the only selective PKD inhibitor
that exhibits in vivo activity [15], clearly showing the need for more diverse, structurally dis-
tinct, and in vivo-active leads for further drug development. Here, we describe the in vitro and
in vivo inhibition of PKD-mediated prostate tumor growth by a novel chemical inhibitor of
PKD, SD-208.
In exploring putative binding modes of SD-208, we employed molecular modeling to deter-
mine key interactions associated with PKD inhibition. As a Type I ATP-competitive inhibitor,
we anticipated SD-208 to exhibit classical hydrogen bond donor and acceptor interactions with
residues in the hinge region [27,40]. Our modeling efforts indicated such hydrogen bond for-
mation between SD-208’s pteridine core and the amino acid backbone of Leu662. Another fea-
ture of inhibition is described by a potentially critical contact between the nitrogen of the 4-
aminopyridine and the charged side chain of Lys612. Primary sequence alignment indicates
that Lys612 in PKD1 is a critical conserved residue required for ATP binding [41]. Previously
reported modeling studies from Novartis suggested key contacts between their two PKD inhib-
itors and the charged side chain of Lys612 [18]. Their model positions a hydrogen bond accepter
near Lys612 and their SAR analysis confirms this chemical feature as a critical component for
inhibition. Our model of SD-208 locates the nitrogen of 4-aminopyridine near Lys612 where it
can act as a hydrogen bond acceptor. Additionally, the SAR analysis further supports the no-
tion that this nitrogen atom is important for PKD inhibition. Lastly, the phenyl ring of SD-208
is found in a conserved hydrophobic region near the entrance of the ATP binding site. Tradi-
tionally, this region is largely solvent exposed and can be exploited by both polar and hydro-
phobic groups [42]. Our PKD homology model presents the disubstituted phenyl ring between
the hydrophobic amino acids Leu589 and Leu713, which may dictate the tolerance of aromatic
substitutions. Therefore, our molecular modeling of SD-208 provided insights into the mecha-
nism of inhibition and suggested key amino acid interactions associated with SD-208 binding.
SD-208 inhibited the growth of PC3 prostate cancer cells with an IC50 of 17μM, and its anti-
proliferative activity was reversed by overexpression of PKD1 and PKD3, indicating inhibition
of PKD accounts for the anti-proliferative effect of SD-208. This finding agrees our previous re-
port that knockdown of PKD3, a predominantly expressed PKD isoform in PC3 cells, causes
dramatic arrest in cell proliferation [10]. Additionally, we have shown for the first time that
SD-208 caused systemic inhibition of tumor growth in vitro and in vivo in a prostate tumor xe-
nograft model through inhibition of PKD, suggesting that this agent could potentially be ex-
ploited as a therapeutic agent for prostate cancer treatment. In this study, we have also
demonstrated that SD-208 significantly blocked prostate cancer cell invasion. However, this ef-
fect may be primarily mediated through the inhibition of transforming growth factor β recep-
tor I (TGF-βRI) since SD-208 has previously been reported as a TGF-βRI inhibitor [19] and
several studies have shown that SD-208 blocked tumor invasion and metastasis by targeting
SD-208 as a Novel PKD Inhibitor in Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0119346 March 6, 2015 15 / 19
TGF-βRI [19,43]. Other than TGF-βRI, inhibition of PKD may also account in part for this ef-
fect since our previous data have shown that inactivation of PKD retarded prostate cancer cell
migration/invasion [22,24].
In the present study, we also demonstrated a novel molecular mechanism through which
SD-208 inhibited prostate cancer cell proliferation. Our data showed that SD-208 exerted a
strong anti-proliferative effect against prostate cancer cells by inducing G2/M arrest. The eu-
karyotic cell cycle progression is regulated by cyclin-dependent kinases (Cdks) and Cyclins.
Progression through G1 into S phase is regulated by the Cyclin A-Cdk2 and Cyclin E-Cdk2
complexes, while Cyclin B-Cdc2 plays a role in G2/M phase transition [34]. Cip/p21 is a uni-
versal inhibitor of CDKs that also regulates the G2/M phase transitions by binding to CDK-Cy-
clin complex and inhibits its kinase activity [35]. Cdc25C is another critical regulator of Cdc2-
Cyclin B1 kinase activity and control cell cycle progression by dephosphorylating and activat-
ing CDKs. Consistent with these notions, we observed an increase in the protein level of inhibi-
tory p21 in both the cells lines. An increased phosphorylation of Cdc2 accompanied by a
decreased Cdc25C protein and phosphorylation was also observed in both cell lines treated
with SD-208. The increased Cdc2 phosphorylation was likely due to reduced Cdc25C protein
level which prevented it from dephosphorylating Cdc2, thereby resulting in enhanced Cdc2
phosphorylation. Taken together, the induction of p21 at early stage, along with the increased
p-Cdc2 as a result of the downregulation of Cdc25c at late stage, lies at the base of the mecha-
nism through which SD-208 induced G2/M arrest.
In conclusion, this study identified SD-208 as a novel, potent, and in vivo active small mole-
cule PKD inhibitor. We showed that this agent was orally bioavailable and blocked prostate
cancer cells proliferation in vitro and in vivo. A series of analogs of SD-208 established the first
PKD-related SAR of this lead structure and determined that an electron-deficient aromatic
ring is preferred in zone 1, and that the 4-aminopyridine in zone 2 is essential for activity. For
the first time, our study elucidated a unique molecular mechanism of action of SD-208 through
induction of p21 along with increased phosphorylation of Cdc2 and Cdc25C, which contribut-
ed to G2/M arrest in prostate cancer cell proliferation. Our computational analyses provided
additional insights into the possible molecular interactions of SD-208 with PKD and would
help in optimizing SD-208 and its congeners for enhanced therapeutic efficacy as potential
anticancer agents.
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